About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

VA Spending on Hospital and Medical Care Exceeds $112 Billion Annually ENGLEWOOD, Colo., Dec. 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States. This collaboration reflec ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

ENGLEWOOD, Colo., Dec. 12, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced highlights from a recent study comparing its NiCO™ laser pulse oximeter to conventional LED pulse oximeters for the effects of skin pigmentation on SpO2 measurements conducted by the University of Californi ...

ENGLEWOOD, Colo., Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has completed its clinical verification trial for their NiCO™ pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University.Trial completion is a key milestone required by the FDA ...

ENGLEWOOD, Colo., Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member.The Open Oximetry Project, an initiative led by the University of California, San Francisco' ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

财务数据和关键指标变化 - 第三季度净收入为5000万美元，较2023年第三季度的4990万美元略有增长 [10] - 第三季度净利润为240万美元，每股摊薄收益为0.07美元，较2023年第三季度的360万美元和0.10美元有所下降 [11] - 现金流来自运营的金额为710万美元，年初至今为1030万美元，现金余额为3760万美元，较第二季度的3090万美元增长22% [11] 各条业务线数据和关键指标变化 - 设备收入为1490万美元，较去年同期的1690万美元下降 [10] - 供应品收入为3510万美元，较去年同期的3310万美元增长 [10] - 康复产品在总订单中的比例从2022年的低双位数增长至2024年第一季度的25%，并在第三季度进一步增长至31% [7] 各个市场数据和关键指标变化 - 第三季度订单同比增长13%，但由于销售代表的调整，订单增长率有所放缓 [10][12] - 预计2024年净收入将增长约9%，达到2亿美元 [7][12] 公司战略和发展方向和行业竞争 - 公司专注于非阿片类疼痛管理解决方案和患者监测解决方案的开发，计划在未来继续多样化收入来源 [3][4] - 新产品TensWave获得FDA批准，旨在提供有效的疼痛缓解 [6] - Zynex监测解决方案的NiCO激光脉搏血氧仪正在进行临床试验，预计将在2025年中期获得FDA批准 [8][9] 管理层对经营环境和未来前景的评论 - 管理层对未来的订单增长持乐观态度，预计第四季度订单同比增长17% [15] - 公司在销售代表的选择和培训上进行了优化，以提高销售效率 [21] - 管理层认为监测部门将长期盈利，尽管短期内需要时间来实现 [24] 其他重要信息 - 公司在第三季度的销售和市场费用为2070万美元，较去年同期的2210万美元有所下降 [11] - 管理层表示，尽管没有在第三季度进行股票回购，但股票回购计划仍然开放 [19] 总结问答环节所有的提问和回答 问题: 关于订单增长的减缓 - 管理层表示，第三季度订单增长减缓主要是由于销售代表的调整，预计第四季度将恢复到双位数的增长 [15] 问题: 关于战略审查过程的更新 - 管理层提到战略审查仍在进行中，已收到几份意向书，但没有立即的关闭时间表 [16] 问题: TensWave的适应症 - 管理层表示，TensWave与NexWave不会同时使用，TensWave是针对特定情况的高质量设备 [18] 问题: 第三季度是否有股票回购 - 管理层确认第三季度没有进行股票回购，但计划仍然开放 [19] 问题: 康复业务的收入情况 - 管理层表示，康复产品的订单比例持续增长，接近10%的业务收入 [20] 问题: 未来销售代表的增加 - 管理层预计未来18个月将每月增加10名销售代表，以填补800个地理区域 [21] 问题: NiCO脉搏血氧仪的市场推广 - 管理层表示将在2025年第一季度决定市场推广策略，初期将采取控制性发布 [22] 问题: 监测部门的盈利能力 - 管理层认为监测部门将长期盈利，尽管需要时间来实现 [24]

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.04, delivering a surprise of -50%.Over the last four quarters, the company has surpas ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc. (Exact name of registrant as specified in its charter) Common Stock, par value $0.001 p ...